ASH 2021 | When should patients with NHL be referred for CAR T-cell therapy?
LaQuisa Hill
• 13 Dec 2021
LaQuisa Hill, MD, Texas Children’s Hospital, Houston Methodist Hospital, Houston, TX, discusses the optimal time for patients with non-Hodgkin lymphoma (NHL) to receive chimeric antigen receptor (CAR) T-cell therapy. For patients with T-cell lymphoma, CAR-T cell therapy is recommended if they failed first-line therapy and earlier referrals can improve the quality of the product, as well as decrease waiting times for patients who need treatment. Cells can additionally be collected and frozen for later use, which reduces the need for cells that have been previously exposed to lymphodepleting agents. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
